Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

istrative expenses is primarily due to cost savings related to recent restructurings.

The Company's balance sheet on September 30, 2008 reflected total assets of $207.7 million, including cash and investments of $118.2 million compared with balances at December 31, 2007 of $276.7 million and $179.4 million, respectively. The Company expects to end 2008 with approximately $100 million in cash and investments.

"We are pleased with the progress of our GnRH program, especially the recent positive results of our 603 study where once a day elagolix showed profound efficacy with minimal impact on bone mineral density. We are also nearing completion of the final preclinical studies of urocortin 2 to allow for long-term Phase II clinical studies and our scientists have just recently identified a clinical candidate from our VMAT2 development program for movement disorders," said Kevin Gorman, Chief Executive Officer and President of Neurocrine Biosciences. "While we are making great strides in advancing our pipeline, we continue to prioritize expenditures and diligently manage our cash burn."

R & D Pipeline Update

Neurocrine's clinical development group and corporate partners have five programs in clinical development. Neurocrine scientists continue to supply Neurocrine's pipeline to meet the Company-wide goal of bringing one new compound into development each year.

Elagolix for Endometriosis

The Company recently announced the positive safety and efficacy results from the completed 6-month treatment phase of its Phase IIb clinical trial (PETAL Study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix.

The primary endpoint, percent change from baseline in mean bone mineral density (BMD) demonstrated elagolix did not induce significant bone loss over the six month treatment period. Additionally, elagolix also met the secondary endpoints of improvement in endometrios
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014  Sangamo BioSciences, Inc. (NASDAQ: SGMO ... and accomplishments. For the second quarter ... loss of $7.0 million, or $0.10 per share, compared ... per share, for the same period in 2013. As ... equivalents, marketable securities and interest receivable of $236.7 million. ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire-iReach/ -- Think Drinks are ... for the long term. They are the first functional ... sustained energy as an alternative to the temporary fix ... on Indiegogo on July 29, 2014, with hopes to ... Photo - http://photos.prnewswire.com/prnh/20140723/129697 ...
(Date:7/23/2014)... -- Having the right people at the table for significant ... and achieving clinical and operational goals. The 22 nd ... 20-22, 2014, in San Diego , ... experts discussing how partnerships have positively impacted their objectives. ... Executive Officer of Cape Regional Medical Center located in ...
(Date:7/23/2014)... MOINES, Iowa (PRWEB) July 23, 2014 ... join the business as vice president of Agricultural Biotechnology ... Mendel Biotechnology where he served most recently as president, ... extensive biotechnology and business leadership in the seed and ... Pioneer,” said Paul E. Schickler , president of ...
Breaking Biology Technology:Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9truBrain Neuroscientists To Launch More Effective, Healthier Alternative To Energy Drinks On Indiegogo 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3
... insulin and Apo ... AI programs - ... TSX symbol: SBS, CALGARY, May 9 /PRNewswire-FirstCall/ - ... cardiovascular diseases, today announced its,2008 first quarter operational and financial results., Highlights, ...
... Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today that ... America 2008 Healthcare Conference on May 14, 2008 at ... Four Seasons Hotel in Las,Vegas, Nevada. Dominic P. Behan, ... scheduled to provide an overview of the,company, including its ...
... and Attract Additional Investors ... Company Enters Next Growth Phase, SAN DIEGO, May 8 ... today announced the reverse split of 1 for 7 shares of ... Shareholders Meeting earlier today., The record date for the reverse ...
Cached Biology Technology:SemBioSys announces first quarter 2008 financial and operational results 2SemBioSys announces first quarter 2008 financial and operational results 3SemBioSys announces first quarter 2008 financial and operational results 4SemBioSys announces first quarter 2008 financial and operational results 5SemBioSys announces first quarter 2008 financial and operational results 6SemBioSys announces first quarter 2008 financial and operational results 7SemBioSys announces first quarter 2008 financial and operational results 8SemBioSys announces first quarter 2008 financial and operational results 9SemBioSys announces first quarter 2008 financial and operational results 10SemBioSys announces first quarter 2008 financial and operational results 11SemBioSys announces first quarter 2008 financial and operational results 12Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 2Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference 3CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Company's Common Stock and Trading in Post-split Shares Begins May 9, 2008 2CardioDynamics Shareholders Approve One-for-Seven Reverse Split of Company's Common Stock and Trading in Post-split Shares Begins May 9, 2008 3
(Date:7/24/2014)... BRUNSWICK, N.J. A yearlong study funded by the ... the Edward J. Bloustein School of Planning and Public ... owners in Sandy-affected towns are skeptical about the likelihood ... online survey respondents, 45 percent indicated they were "pessimistic" ... affected by Superstorm Sandy would be rebuilt better than ...
(Date:7/24/2014)... This news release is available in German . ... that there are 300 million asthma sufferers worldwide, a ... up to 30% of the global population contending with ... inflammatory diseases can also affect other organs and parts ... occur in the intestine (in the form of inflammatory ...
(Date:7/24/2014)... Conn. , July 24, 2014 NXT-ID, Inc., ... m-commerce market, announces its next generation smart wallet, Wocket™, was recently ... Anita Finley interviewed Gino Pereira , ... over thirty minutes. Mr. Gino ... bulky wallets full of credit cards and walks host ...
Breaking Biology News(10 mins):Rutgers study explores attitudes, preferences toward post-Sandy rebuilding 2New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 2Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 3Boomer Times Gets to Know NXT-ID's Next Generation Wocket Smart Wallet; Practical, Secure and Easy to Use 4
... 2, 2013 Elsevier, a world-leading provider of scientific, ... the launch of a new open access journal: ... plant science is increasingly becoming an interdisciplinary domain of ... trend is largely fuelled by the last decade,s technical ...
... University,s Institute for Genomic Biology and the Coordinated Science ... top faculty in genomic and computational sciences to create ... genomic breakthroughs. One human genome is made up ... books that could take nearly 95 years to read, ...
... Brigham and Women,s Hospital have shown that they can ... them to develop into nearly pure populations of different ... could develop and test new drugs to treat diseases ... most other body tissues, has a small store of ...
Cached Biology News:Elsevier announces the launch of open access journal: Current Plant Biology 2Illinois initiative creates futuristic facility 2Researchers unlock a new means of growing intestinal stem cells 2Researchers unlock a new means of growing intestinal stem cells 3
Canine Chondrocytes (CnC) (500,000 cells)...
... Workstation brings together UV irradiation and antimicrobial ... against PCR contamination! Quickly inactivate DNA ... a clean environment with antimicrobial coated stainless ... within minutes with built-in 30-minute timer ...
B-FABP (FL-132)...
... Varioskan is a high performance ... dispenser and incubator. With the advanced ... and reliability for drug discovery assay ... for fluorescence intensity, time-resolved fluorescence and ...
Biology Products: